What is the difference between homologous and heterologous desensitization?

Homologous desensitization affects only the receptor that has bound agonist and depends on receptor kinases phosphorylating the occupied receptor; heterologous desensitization is produced by second-messenger-activated kinases that phosphorylate receptors regardless of occupancy, so several receptor pathways are dampened at once.

Is desensitization permanent?

Not usually. Internalised receptors are often dephosphorylated and recycled to the cell surface, restoring responsiveness (resensitization); a more lasting loss of responsiveness occurs when receptors are degraded and total receptor number falls (downregulation).

Desensitization and Mechanism-Based Tolerance

Desensitization is the loss of receptor responsiveness during continued agonist exposure, and it is the principal molecular mechanism behind pharmacodynamic, or mechanism-based, tolerance. For G protein-coupled receptors, agonist occupancy triggers phosphorylation, arrestin binding, uncoupling from G proteins, and internalisation, so that the same stimulus produces a smaller signal over time; reversal of these steps allows the receptor to resensitize.

Definition

Desensitization is the diminished responsiveness of a receptor system during continued or repeated agonist exposure, mediated by receptor phosphorylation, arrestin binding, uncoupling, internalisation, and downregulation; mechanism-based tolerance is the reduction in drug effect that results from these adaptations in the responding system.

Scope

This topic covers the cellular mechanisms by which receptor signalling is attenuated during sustained stimulation, the distinction between homologous and heterologous desensitization, and how these processes underlie mechanism-based tolerance. It is a reference treatment of receptor regulation and provides no dosing or treatment advice.

Core questions

How does a receptor become less responsive while an agonist is still present?
What distinguishes homologous from heterologous desensitization?
How does desensitization reverse so that the receptor resensitizes?

Key concepts

Receptor desensitization
Homologous versus heterologous desensitization
Receptor phosphorylation
G protein-coupled receptor kinases (GRKs)
Arrestins
Receptor internalisation and recycling
Receptor downregulation
Resensitization

Key theories

GRK/arrestin desensitization model: Agonist-occupied G protein-coupled receptors are phosphorylated by G protein-coupled receptor kinases, which promotes binding of arrestins that sterically uncouple the receptor from its G protein and target it for internalisation; this sequence explains rapid homologous desensitization and, through subsequent dephosphorylation and recycling, resensitization.

Mechanisms

For G protein-coupled receptors, agonist binding stabilises a conformation that is phosphorylated by G protein-coupled receptor kinases on the agonist-occupied receptor, a homologous process specific to the activated receptor. Phosphorylation recruits arrestins, which sterically uncouple the receptor from its G protein and act as adaptors for clathrin-mediated internalisation. Internalised receptors can be dephosphorylated and recycled to the surface, restoring responsiveness (resensitization), or directed to degradation, reducing total receptor number (downregulation). Heterologous desensitization, by contrast, is produced by second-messenger-activated kinases such as protein kinase A or C that phosphorylate receptors regardless of occupancy, dampening multiple receptor pathways at once. The balance between desensitization, internalisation, recycling, and degradation sets how quickly and how completely the response declines and recovers, and these adaptations are the cellular basis of mechanism-based tolerance.

Clinical relevance

Desensitization mechanisms explain, at the molecular level, why a receptor-mediated drug effect can wane during continued exposure, which helps the health sciences interpret pharmacodynamic tolerance and time-course data. The content is for reference and education on receptor regulation and is not a basis for dosing or individual treatment decisions.

Evidence & guidelines

The mechanistic account rests on molecular pharmacology reviews of G protein-coupled receptor desensitization, the roles of receptor kinases and arrestins, and receptor endocytosis and resensitization, complemented by standard textbook treatments. There are no clinical guidelines specific to this cellular topic.

History

Work from the 1980s onward established that agonist-occupied receptors are phosphorylated and bind arrestins, uncoupling them from their effectors. Through the 1990s and early 2000s, studies by Ferguson, Lefkowitz, and colleagues defined the roles of G protein-coupled receptor kinases, arrestins, and receptor internalisation in both desensitization and resensitization, providing the molecular foundation for mechanism-based pharmacodynamic tolerance.

Key figures

Stephen S. G. Ferguson
Robert J. Lefkowitz
Marc G. Caron

Seminal works

ferguson-1998
kohout-2003
ferguson-2001

Frequently asked questions

What is the difference between homologous and heterologous desensitization?: Homologous desensitization affects only the receptor that has bound agonist and depends on receptor kinases phosphorylating the occupied receptor; heterologous desensitization is produced by second-messenger-activated kinases that phosphorylate receptors regardless of occupancy, so several receptor pathways are dampened at once.
Is desensitization permanent?: Not usually. Internalised receptors are often dephosphorylated and recycled to the cell surface, restoring responsiveness (resensitization); a more lasting loss of responsiveness occurs when receptors are degraded and total receptor number falls (downregulation).